# US 6,727,279 B2 · Arylsulphonamides and analogues

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,279 B2
- Document ID: US6727279B2
- Status: Granted
- Kind: B2
- Application number: 10/225,823
- Filed: 2002-08-21
- Published: 2003-04-17
- Granted: 2004-04-27
- Earliest claimed: 1998-08-19
- Assignees: Bayer Aktiengesellschaft
- Inventors: Joachim Mittendorf; Jürgen Dressel; Michael Matzke; Jörg Keldenich; Frank Mauler; Jean-Marie-Victor de Vry; Jürgen Franz; Peter Spreyer; Verena Vöhringer; Joachim Schumacher; Michael-Harold Rock; Ervin Horvàth; Arno Friedl; Klaus-Helmut Mohrs; Siegfried Raddatz; Reinhard Jork
- Web page: https://patentgrep.com/patent/US6727279B2

## CPC

- C07D 307/80: Radicals substituted by oxygen atoms
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 7/06: Antianaemics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/06: Antiasthmatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 309/65: of a saturated carbon skeleton
- C07C 2602/08: the other ring being five-membered, e.g. indane
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present invention relates to novel arylsulphonamides and analogues, to processes for their preparation and to their use for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy, craniocerebral trauma, pain and spasticity.

## Claims

### Claim 1

Compounds of the general formula (I)
R1-A-D-E-G-L-R2 (I)
in which
R1 represents a radical of the formula
in which
the ring systems listed above are optionally substituted, optionally geminally, by one or more identical or different substituents selected from the group consisting of:
halogen, carboxyl, hydroxyl, phenyl, (C1-C6)-alkoxy, (C1-C6)-alkoxycarbonyl, (C1-C8)-alkyl, which for its part may be substituted by halogen, (C1-C6)-alkylsulphonyloxy, azide, amino, mono(C1-C6)-alkylamino, di(C1-C6)-alkylamino or hydroxyl,
a group of the formula —(CO)b-NR4R5,
in which
b represents a number 0 or 1,
R4 and R5 are identical or different and independently of one another represent hydrogen, phenyl, (C1-C6)-acyl, cyclo(C4-C7)-acyl benzoyl or (C1-C6)-alkyl, which is optionally substituted by amino, mono(C1-C6)-alkylamino, di(C1-C6)-alkylamino,
or
R4 and R5 together with the nitrogen atom form a 5- or 6-membered saturated heterocycle which may optionally contain one or more further heteroatom(s) from the group consisting of S and O and/or one or more radical(s) of the formula —NR8,
in which
R8 represents hydrogen, (C1-C6)-alkyl or (C1-C6)-acyl,
and
a group of the formula —NR6—SO2—R7
in which
and
R6 represents hydrogen, phenyl, (C1-C6)-alkyl or (C1-C6)-acyl,
R7 represents phenyl or (C1-C6)-alkyl,
and a radical of the formula
in which
c represents a number 1, 2, 3, 4, 5 or 6,
R9 and R10 are identical or different and represent hydrogen or (C1-C6)-alkyl,
T represents a radical of the formula —(CH2)d—,
in which
d represents a number 1, 2, 3, 4, 5 or 6,
or
T represents a moiety of an amino acid radical of the formula
in which
R13 and R14 are identical or different and represent hydrogen or methyl,
or
R13 represents hydrogen or methyl
and
R14 represents (C3-C8)-cycloalkyl or (C6-C10)-aryl or hydrogen,
or
(C1-C8)-alkyl,
where the (C1-C8)-alkyl is optionally substituted by methlythio, hydroxyl, mercapto, guanidyl or by a group of the formula —NR15R16 or —NR17—OC—,
in which
R15 and R16 independently of one another represent hydrogen, (C1-C8)-alkyl or phenyl
and
R17 represents hydroxyl, benzyloxy, (C1-C8)-alkoxy or the group —NR15R16 listed above,
or the (C1-C8)-alkyl is optionally substituted by (C3-C6)-cycloalkyl or phenyl, which for its part is substituted by hydroxyl, halogen or (C1-C6)-alkoxy or amino,
or the (C1-C8)-alkyl is optionally substituted by imidazolyl or indolyl, in which the corresponding —NH functions are optionally protected by (C2-C6)-alkyl or by an amino protective group,
R11 and R12 are identical or different and represent hydrogen, (C1-C6)-alkyl or a typical amino protective group,
or
R11 and R12 together with the nitrogen atom form a 5-to 6-membered saturated heterocycle, which may optionally contain a further heteroatom from the group consisting of S and O or a radical of the formula —NR18,
in which
R18 represents hydrogen, (C1-C6)-alkyl or phenyl,
A and E
D represents an oxygen atom or represents a radical of the formula —S(O)e— or —N(R19)—,
in which
e represents a number 0, 1 or 2,
R19 represents hydrogen, (C1-C6)-alkyl or (C1-C6)-acyl,
G represents doubly attached (C6-C10)-aryl which is optionally substituted by one or more identical or different substituents selected from the group consisting of:
hydroxyl, trifluoromethyl, carboxyl, halogen, (C1-C6)-alkyl, hydroxy(C1-C6)-alkyl, (C1-C6)-alkoxy, (C1-C6)-alkoxycarbonyl, and groups of the formulae —CO—O—(CH2)f—NR20R21, —NR22—SO2R23, —(CH2)g—(CO)h—NR24R25 and —OR26,
in which
f represents a number 1, 2, 3 or 4,
g and h are identical or different and represent a number 0 or 1,
R20 and R21 have the meaning of R4 and R5 given above,
R22 has the meaning of R6 given above,
R23 has the meaning of R7 given above,
R24 and R25 have the meaning of R4 and R5 given above,
or independently of one another represent a radical of the formula
—(CH2)i—NR27R28,
in which
i represents a number 1, 2, 3 or 4,
and
R27 R28 have the meaning of R4 and R5 given above,
R26 represents (C6-C10)-aryl,
L represents a radical of the formula,
where the left-hand side of the radicals is attached to G,
R2 represents (C6-C10)-aryl or represents a 5- to 7-membered saturated or aromatic heterocycle having up to 3 heteroatoms from the group consisting of S, N and O, which are optionally substituted by one or more identical or different substituents selected from the group consisting of:
halogen, trifluoromethyl, nitro, amino and (C1-C6)-alkyl,
or
represents the radical of the formula
or morpholine, or represents C3-C8-cycloalkyl, or
represents (C1-C12)-alkyl, (C2-C12)-alkenyl or (C2-C12)-alkinyl, which are optionally substituted by one or more identical or different substituents selected from the group consisting of:
halogen, trifluoromethyl, hydroxyl, cyano, azido, (C1-C6)-alkoxy, (C1-C6)-perfluoroalkoxy, partially fluorinated (C1-C6)-alkoxy, a radical of the formula
in which
R38 and R39 have the meaning of R4 and R5 given above,
phenyl, optionally substituted by one or more identical or different substituents selected from the group consisting of:
halogen, nitro, hydroxyl, (C1-C6)-alkyl, (C1-C6)-alkoxy and a group of the formula —NR40R41,
in which
R40 and R41 are identical or different and represent hydrogen or (C1-C6)-alkyl or (C1-C6)-acyl,
and a 5- to 6-membered aromatic heterocycle having up to three heteroatoms from the group consisting of S, N and O, optionally substituted by one or more identical or different substituents selected from the group consisting of:
halogen, nitro, hydroxyl, (C1-C6)-alkyl, (C1-C6)-alkoxy and a group of the formula —NR40R41
in which
R40 and R41 are as defined above,
or
L and R2 together represent a radical of the formula
and pharmaceutically acceptable salts thereof,
with proviso that R1 does not represent an unsubstituted radical.

### Claim 2 (depends on 1)

Compounds of the general formula (I) according to claim 1,
R1 represents a radical of the formula
and where the ring systems listed above are optionally substituted, optionally geminally, by one or more identical or different substituents selected from the group consisting of:
fluorine, chlorine, carboxyl, hydroxyl, (C1-C4)-alkoxy, (C1-C5)-alkoxycarbonyl or (C1-C6)-alkyl, which for its part may be substituted by fluorine, chlorine or hydroxyl, and a radical of the formula
in which
c represents a number 1, 2, 3, 4, 5 or 6,
R9 and R10 are identical or different and represent hydrogen or (C1-C6)-alkyl,
T represents a radical of the formula —(CH2)d—,
in which
d represents a number 1, 2, 3, 4, 5 or 6,
or
T represents a moiety of an amino acid radical of the formula
in which
R13 and R14 are identical or different and represent hydrogen or (C1-C6)-alkyl,
or
R13 represents hydrogen or methyl
and
R14 represents cyclopropyl, cyclopentyl, cyclohexyl, phenyl or hydrogen, or represents (C1-C6)-alkyl,
where the (C1-C6)-alkyl is optionally substituted by methlythio, hydroxyl, mercapto, guanidyl or by a group of the formula —NR15R16 or —NR17—OC—,
in which
R15R16 independently of one another represent hydrogen, (C1-C6)-alkyl or phenyl
and
R17 represents hydroxyl, benzyloxy, (C1-C6)-alkoxy or the group —NR15R16 listed above,
or the (C1-C6)-alkyl is optionally substituted by cyclopropyl, cyclopentyl, cyclohexyl or phenyl, which for its part is substituted by hydroxyl, fluorine, chlorine, bromine or (C1-C4)-alkoxy or amino,
or
R11 and R12 are identical or different and represent hydrogen or (C1-C4)-alkyl,
or
R11 and R12 together with the nitrogen atom form a morpholinyl piperidinyl or piperazinyl ring,
A and E,
D represents an oxygen atom,
G represents doubly attached phenyl or pyridyl, which are optionally substituted by one or more identical or different substituents selected from the group consisting of:
hydroxyl, trifluoromethyl, carboxyl, halogen, (C1-C4-alkyl, hydroxy(C1-C4)alkyl, (C1-C4)-alkoxy, (C1-C4)-alkoxycarbonyl and groups of the formulae —CO—O—(CH2)f—NR20R21, —NR22—SO2R23, —(CH2)g—(CO)h—
NR24R25 and OR26,
in which
f represents a number 1, 2, 3 or 4,
g and h are identical or different and represent a number 0 or 1,
R20 and R21 have the meaning of R4 and R5 given above,
R22 has the meaning of R6 given above,
R23 has the meaning of R7 given above,
R24 and R25 have the meaning of R4 and R5 given above, or independently of one another represent a radical of the formula —(CH2)i—NR27 R28,
in which
i represents a number 1, 2 or 3,
and
R27 and R28 have the meaning of R20 and R21 given above,
R26 represents phenyl or naphthyl,
L represents a radical of the formula
where the left-hand side of the radicals is attached to G,
R2 represents (C1-C1o)-alkyl which is optionally substituted more identical or different substituents selected from the group consisting of:
fluorine, chlorine, bromine, phenyl, trifluoromethyl, hydroxyl, azido, (C1-C4)-alkoxy, (C1-C5)-perfluoroalkoxy or partially fluorinated (C1-C4)alkoxy
and pharmaceutically acceptable salts thereof.

### Claim 3 (depends on 1)

Compounds of the general formula (I), according to claim 1
in which
R1 represents a radical of the formula
and where the ring systems listed above are optionally substituted by one or more identical or different substituents selected from the group consisting of:
chlorine, fluorine, hydroxyl, (C1-C3)-alkoxy or (C1-C4)-alkyl, which for its part may be substituted by hydroxyl,
A and E represent a bond,
D represents an oxygen atom,
G represents doubly attached phenyl which are optionally substituted by one or more identical or different substituents selected from the group consisting of:
hydroxyl, trifluoromethyl, carboxyl, fluorine, chlorine, bromine, (C1-C3)-alkyl, hydroxy(C1-C3)alkyl or (C1-C3)-alkoxy
L represents a radical of the formula
where the left-hand side of the radicals is attached to G,
R2 represents (C1-C8)-alkyl, which is optionally substituted by one or more identical or different substituents selected from the group consisting of:
fluorine, chlorine, bromine, phenyl, trifluoromethyl or trifluoromethyl-substituted (C1-C4)-alkoxy,
and pharmaceutically acceptable salts thereof.

### Claim 4 (depends on 1)

Compounds of the general formula (I), according to claim 1,
in which
R1 represents a radical of the formula
A and E represent bonds,
D represents an oxygen atom,
G represents doubly attached phenyl, which is optionally substituted by fluorine, chlorine or bromine,
L represents a radical of the formula
where the left-hand side of the radical is attached to G,
R2 represents (C1-C4)-alkyl, which is optionally substituted by fluorine or trifluoromethyl,
and pharmaceutically acceptable salts thereof.

### Claim 5

Compounds selected from the group consisting of

### Claim 6 (depends on 1)

A process for preparing novel arylsulphonamides and analogues according to claim 1, characterized in that
[A] compounds of the general formula (IV)
R1-A-D-E-G-M-H (II)
in which
R1, A, D, E and G have the meaning given in claim 1 and
M represents oxygen or
in which
R42 represents hydrogen or (C1-C4-alkyl,
are reacted with compounds of the general formula (III)
R43—U—R2 (III)
in which
R2 has the meaning given in claim 1,
R43 represents halogen,
U represents a radical of the formula —SO2—, —SO—, —CO—, —P(O)(OR37)— or a single bond,
in which
R37 has the meaning given in claim 1,
to give compounds of the general formula (Ia)
R1-A-D-E-G-M-U—R2 (Ia)
in which
R1, A, D, E, G, and R2 have the meaning given in claim 1
and M and U have the meaning given above,
in inert solvents,
or
[B] compounds of the general formula (II)
are initially reacted with trialkylsilyl chlorosulphonates, admixed with an acid and then reacted with a chlorinating agent, to give a compound of the general formula (IV)
R1-A-D-E-G-M-SO2—Cl (IV)
in which
R1, A, D, E, and G have the meaning given in claim 1
and M has the meaning given above;
followed by reaction with compounds of the general formula (V)
H—V—R2 (V)
in which
R2 has the meaning given in claim 1 and
V represents oxygen or nitrogen,
to give compounds of the general formula (Ib)
R1-A-D-E-G-M-SO2—V—R2 (Ib)
in which
R1, A, D, E, G, and R2 have the meaning given in claim 1
and M and V have the meaning given above,
in inert solvents in the presence of Bzl-NEt3+Cl− and a base,
or
[C] compounds of the general formula (VI)
R1-A-D′-H (VI)
in which
R1 and A have the meaning given in claim 1 and
D represents oxygen, sulphur or —N(R19)— and
R19 has the meaning given above,
are reacted with compounds of the general formula (VII)
R44-E-G-SO2—NH—R2 (VII)
in which
E, G and R2 have the meaning given in claim 1 and
R44 represents a leaving group,
to give compounds of the general formula (Ic)
R1-A-D′-E-G-SO2—NH—R2 (Ic)
in which
R1, A, D′, E, G and R2 have the meaning given in claim 1, or
[G] compounds of the general formula (Ih)
in which
A, D, E, G, L and R2 have the meaning given in claim 1,
are converted by free-radical bromination, in an inert solvent into compounds of the general formula (Ii)
in which
A, D, E, G, L and R2 have the meaning given in claim 1,
and one of the substituents W or X represents bromine and the other represents hydrogen,
and subsequently reacted with compounds of the general formula (IX)
CH2(CO2R51)2 (IX)
in which
R51 represents (C1-C6)-alkyl and
in inert solvents, to give compounds of the general formula (Ij)
R52-A-D-E-G-L-R2 (Ij)
in which
A, D, E, G, L and R2 have the meaning given in claim 1 and
R52 represents a radical of the formula
in which
R51, W and X have the meaning given above,
to give compounds of the general formula (X)
in which
A, D, E, G, L, and R2 have the meaning given in claim 1
and W and R51 have the meaning given above,
and finally reduced to the methylhydroxy function,
or
[H] in the case that R1 represents the rings listed above, which are substituted by the radical of the formula
in which
c, T, R9, R10, R11 and R12 have the meaning given in claim 1,
compounds of the general formula (XI)
R1—(CR9R10)c—OH (XI)
are reacted with compounds of the general formula (XII)
in which
T has the meaning given in claim 1,
R11′ represents hydrogen
and
R12′ represents one of the amino protective groups listed above,
in inert solvents,
and the amino protective group is cleaved off,
and, in the last step, a reduction with BH3×S(CH3)2 in tetrahydrofuran is carried out,
and, in the case of the pure enantiomers, an HPLC separation is carried,
and, in the case that D=—SO— or —SO2—, an oxidation is carried out on the corresponding thioesters (D=S) by customery methods,
and, in the case of the ammonium compounds, an alkylation is carried out on the corresponding amines.

### Claim 7 (depends on 1)

A pharmaceutical composition which comprises, as an active component, at least one compound according to claim 1 in combination with at least one pharmaceutically acceptable essentially non-toxic vehicle or excipient.

### Claim 8 (depends on 1)

A method for the treatment of neurodegenerative disorders comprising administering to a mammal an effective amount of a compound according to claim 1.

### Claim 9 (depends on 1)

A method for the treatment of cerebral ischaemias and craniocerebral trauma comprising administering to a mammal an effective amount of a compound according to claim 1.

### Claim 10 (depends on 1)

A method for the treatment of pain, emesis, nausea, glaucoma, asthma, anorexia, convulsions, rheumatism, sedation, and mobility disorders comprising administering to a mammal an effective amount of a compound according to claim 1.

### Claim 11 (depends on 1)

A method for the treatment of bacterial or viral infections, autoimmune diseases, inflammatory or autoimmunologically related diseases of the joints of the bone and muscle apparatus, of the internal organs, of the central nervous system, of the sense organs and of the haematogenic system comprising administering to a mammal an effective amount of a compound according to claim 1.

### Claim 12 (depends on 1)

A method for the treatment of migraine and spasticity comprising administering to a mammal an effective amount of a compound according to claim 1.

### Claim 13 (depends on 6)

The process of claim 6, wherein said trialkysilyl chlorosulphonate is trimethylsilyl chlorosulphonate and said chlorinating agent is phosphorus pentachloride.

### Claim 14 (depends on 6)

The process of claim 6, wherein R43 is selected from the group consisting of chlorine and iodine.

### Claim 15 (depends on 6)

The process of claim 6, wherein R44 is selected from the group consisting of fluorine, chlorine, and bromine.

### Claim 16 (depends on 6)

The process of claim 6, wherein said chloroformate is selected from the group consisting of 1-(1-chloro)ethyl chloroformate and methyl chloroformate.

### Claim 17 (depends on 6)

The process of claim 6, wherein said alcohol is methanol.

### Claim 18 (depends on 6)

The process of claim 6, wherein said reducing agent is sodium cyanoborohydrate.

### Claim 19 (depends on 6)

The process of claim 6, wherein R49 is a halogen.

### Claim 20 (depends on 6)

The process of claim 6, wherein said free-radical bromination is performed using N-bromosuccinimide.

### Claim 21 (depends on 6)

The process of claim 6, wherein R12′ is tert-butyloxycarbonyl.

### Claim 22 (depends on 6)

The process of claim 6, wherein, after removal of the amino protective group, the amino group is reductively alkylated or dialkylated with an aldehyde, ketone, or halide.

### Claim 23 (depends on 20)

The process of claim 20, wherein said compound of formula I is esterified.
